The Second School of Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
Zhejiang Shuren University Shulan International Medical College, Department of Cardiovascular Medicine, Hangzhou, Zhejiang, CN.
J Int Med Res. 2023 Oct;51(10):3000605231208599. doi: 10.1177/03000605231208599.
Haemophilia B is a rare inherited bleeding disorder in which patients have impaired coagulation. This study describes a patient with Haemophilia B and paroxysmal supraventricular tachycardia (PSVT) who underwent radio frequency catheter ablation (RFCA). The perioperative replacement therapy with coagulation factor IX (FIX) was agreed upon after an interdisciplinary consultation involving a team of specialists in haematology, cardiovascular medicine and cardiothoracic surgery. There were no obvious bleeding points or complications during the perioperative period following the treatment, nor recurrence of PSVT within a three-year follow-up period. In summary, RFCA can be performed safely in patients with haemophilia B on the premise of developing an individualized perioperative exogenous coagulation factor supplementation regimen based upon an adequate preoperative evaluation and clinical monitoring and management by an interdisciplinary team.
乙型血友病是一种罕见的遗传性出血性疾病,患者凝血功能受损。本研究描述了一例乙型血友病合并阵发性室上性心动过速(PSVT)患者,该患者接受了射频导管消融术(RFCA)。经过血液科、心血管医学和心胸外科专家团队的多学科会诊,确定了围手术期凝血因子 IX(FIX)替代治疗方案。治疗后围手术期无明显出血点或并发症,三年内无 PSVT 复发。综上所述,在充分的术前评估以及多学科团队的临床监测和管理的基础上,制定个体化的围手术期外源性凝血因子补充方案,RFCA 可安全用于乙型血友病患者。